Last updated: 2 July 2024 at 4:12pm EST

Michael DeMane Net Worth




The estimated Net Worth of Michael F Demane is at least $59.7 Million dollars as of 12 April 2023. Mr. Demane owns over 80,291 units of Nevro Corp stock worth over $475,795 and over the last 10 years he sold NVRO stock worth over $58,900,367. In addition, he makes $279,955 as Lead Independent Director at Nevro Corp.

Mr. DeMane NVRO stock SEC Form 4 insiders trading

Michael has made over 38 trades of the Nevro Corp stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 80,291 units of NVRO stock worth $1,445,238 on 12 April 2023.

The largest trade he's ever made was exercising 139,514 units of Nevro Corp stock on 4 October 2016 worth over $2,435,914. On average, Michael trades about 16,787 units every 45 days since 2014. As of 12 April 2023 he still owns at least 101,018 units of Nevro Corp stock.

You can see the complete history of Mr. Demane stock trades at the bottom of the page.





Michael DeMane biography

Michael F. DeMane serves as Lead Independent Director of the Company. Effective January 1, 2017, Mr. DeMane transitioned to non-executive Chairman of the Board. In May 2019, Mr. DeMane became our Lead Director. Mr. DeMane has served on the board of directors of several private companies since 2009, as well as on the board of directors of eResearch Technology, Inc., a public company specializing in contract research clinical services, from July 2008 to April 2012. From March 2009 to June 2010, Mr. DeMane served as a Senior Advisor to Thomas, McNerney & Partners, a healthcare venture firm. Mr. DeMane served as the Chief Operating Officer of Medtronic from August 2007 to April 2008. Prior to his COO role, Mr. DeMane served at Medtronic as Senior Vice President from May 2007 to August 2007, Senior Vice President and President: Europe, Canada, Latin America and Emerging Markets from August 2005 to May 2007, Senior Vice President and President: Spinal, ENT and Navigation from February 2002 to August 2005, and President, Spinal from January 2000 to February 2002. Prior to that, he was President at Interbody Technologies, a division of Medtronic Sofamor Danek, Inc., from June 1998 to December 1999. From April 1996 to June 1998, Mr. DeMane served at Smith & Nephew Pty. Ltd. as Managing Director, Australia and New Zealand, after a series of research and development and general management positions with Smith & Nephew Inc. Mr. DeMane earned a B.S. in Chemistry from St. Lawrence University and an M.S. in Bioengineering from Clemson University.

What is the salary of Michael DeMane?

As the Lead Independent Director of Nevro Corp, the total compensation of Michael DeMane at Nevro Corp is $279,955. There are 13 executives at Nevro Corp getting paid more, with D.Keith Grossman having the highest compensation of $13,877,700.



How old is Michael DeMane?

Michael DeMane is 63, he's been the Lead Independent Director of Nevro Corp since 2019. There are 6 older and 17 younger executives at Nevro Corp. The oldest executive at Nevro Corp is Frank Fischer, 78, who is the Independent Director.

What's Michael DeMane's mailing address?

Michael's mailing address filed with the SEC is C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY, CA, 94065.

Insiders trading at Nevro Corp

Over the last 10 years, insiders at Nevro Corp have traded over $298,472,982 worth of Nevro Corp stock and bought 312,708 units worth $8,709,518 . The most active insiders traders include Ali Behbahani, Holdings A/S Novo, and & Johnson Johnson & Johnson.... On average, Nevro Corp executives and independent directors trade stock every 18 days with the average trade being worth of $161,002. The most recent stock trade was executed by Shawn Mc Cormick on 7 June 2023, trading 7,500 units of NVRO stock currently worth $171,600.



What does Nevro Corp do?

headquartered in redwood city, california, nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. nevro has developed and commercialized the senza spinal cord stimulation (scs) system, an evidence-based neuromodulation platform for the treatment of chronic pain. the senza system is the only scs system that delivers nevro's proprietary hf10 therapy. the nevro® senza® scs system received ce mark in 2010, tga approval in 2011, fda approval in 2015, and is commercially available in europe, australia, and the united states.



What does Nevro Corp's logo look like?

Nevro Corp logo

Complete history of Mr. Demane stock trades at Nevro Corp

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
12 Apr 2023 Michael F Demane
Option 80,291 $18.00 $1,445,238
12 Apr 2023
101,018
22 Jun 2021 Michael F Demane
Sale 6,445 $179.03 $1,153,848
22 Jun 2021
231,277
9 Oct 2020 Michael F Demane
Sale 21,432 $150.35 $3,222,301
9 Oct 2020
236,207
15 Sep 2020 Michael F Demane
Sale 18,028 $146.42 $2,639,660
15 Sep 2020
257,440
2 Sep 2020 Michael F Demane
Sale 3,400 $145.25 $493,850
2 Sep 2020
275,468
27 Aug 2020 Michael F Demane
Sale 18,900 $141.01 $2,665,089
27 Aug 2020
278,868
13 Aug 2020 Michael F Demane
Sale 300 $140.05 $42,015
13 Aug 2020
347,768
10 Aug 2020 Michael F Demane
Sale 87,940 $135.68 $11,931,699
10 Aug 2020
38,054
11 Nov 2019 Michael F Demane
Sale 50,000 $103.70 $5,185,000
11 Nov 2019
429,519
11 May 2018 Michael F Demane
Option 3,631 $18.00 $65,358
11 May 2018
472,516
21 Dec 2017 Michael F Demane
Option 41,572 $3.60 $149,659
21 Dec 2017
468,885
5 Oct 2017 Michael F Demane
Sale 5,000 $93.50 $467,500
5 Oct 2017
427,313
27 Sep 2017 Michael F Demane
Sale 5,000 $91.50 $457,500
27 Sep 2017
432,313
13 Sep 2017 Michael F Demane
Sale 5,000 $89.50 $447,500
13 Sep 2017
42,554
11 Sep 2017 Michael F Demane
Sale 25,000 $87.73 $2,193,250
11 Sep 2017
47,554
1 May 2017 Michael F Demane
Sale 29,800 $96.07 $2,862,886
1 May 2017
485,795
4 Apr 2017 Michael F Demane
Sale 22,200 $93.39 $2,073,258
4 Apr 2017
515,595
28 Mar 2017 Michael F Demane
Option 13,620 $4.33 $58,975
28 Mar 2017
537,795
21 Feb 2017 Michael F Demane
Sale 6,000 $97.30 $583,800
21 Feb 2017
0
30 Nov 2016 Michael F Demane
Option 10,000 $3.60 $36,000
30 Nov 2016
525,920
8 Nov 2016 Michael F Demane
Option 30,000 $3.60 $108,000
8 Nov 2016
515,920
4 Oct 2016 Michael F Demane
Option 139,514 $17.46 $2,435,914
4 Oct 2016
532,424
4 Oct 2016 Michael F Demane
Option 139,514 $17.46 $2,435,914
4 Oct 2016
532,424
22 Aug 2016 Michael F Demane
Sale 13,334 $99.00 $1,320,066
22 Aug 2016
4,255
22 Aug 2016 Michael F Demane
Sale 13,334 $99.00 $1,320,066
22 Aug 2016
4,255
9 Aug 2016 Michael F Demane
Sale 26,667 $91.50 $2,440,031
9 Aug 2016
7,589
9 Aug 2016 Michael F Demane
Sale 26,667 $91.50 $2,440,031
9 Aug 2016
7,589
29 Jul 2016 Michael F Demane
Sale 13,333 $84.00 $1,119,972
29 Jul 2016
14,256
29 Jul 2016 Michael F Demane
Sale 13,333 $84.00 $1,119,972
29 Jul 2016
14,256
11 Jul 2016 Michael F Demane
Sale 13,333 $79.00 $1,053,307
11 Jul 2016
17,589
11 Jul 2016 Michael F Demane
Sale 13,333 $79.00 $1,053,307
11 Jul 2016
17,589
1 Jul 2016 Michael F Demane
Sale 13,333 $74.00 $986,642
1 Jul 2016
20,922
1 Jul 2016 Michael F Demane
Sale 13,333 $74.00 $986,642
1 Jul 2016
20,922
16 May 2016 Michael F Demane
Sale 39,999 $64.77 $2,590,735
16 May 2016
24,255
1 Mar 2016 Michael F Demane
Sale 39,999 $55.63 $2,225,144
1 Mar 2016
30,921
16 Nov 2015 Michael F Demane
Sale 40,001 $50.52 $2,020,851
16 Nov 2015
111,199
1 Sep 2015 Michael F Demane
Sale 40,001 $45.11 $1,804,445
1 Sep 2015
117,866
5 Nov 2014 Michael F Demane
Option 58,906 $3.60 $212,062
5 Nov 2014
617,404


Nevro Corp executives and stock owners

Nevro Corp executives and other stock owners filed with the SEC include: